BioVie Inc. Debt Conversion, Converted Instrument, Amount
BioVie Inc. (BIVI) reported Debt Conversion, Converted Instrument, Amount of $1.15 million for the 12-month period ending 2019-06-30, per its 10-K/A filed 2020-08-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2020-08-07
- BioVie Inc. debt conversion, converted instrument, amount for the quarter ending 2018-09-30 was $1.15M.
- BioVie Inc. debt conversion, converted instrument, amount for fiscal 2019 was $1.15M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|
| 2019-06-30 | $1.15M 10-K/A · filed 2020-08-07 | |
| 2018-09-30 | $1.15M 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |